Eledon Pharmaceuticals Inc Stock Price, News & Analysis

Eledon Pharmaceuticals reported significant advancements in its clinical trials and regulatory approvals for tegoprubart, aimed at preventing organ rejection in kidney transplant patients and treating IgA Nephropathy (IgAN). The FDA cleared IND applications for both indications, allowing for Phase 2 trials to commence. The company has dosed initial patients in an ex-U.S. Phase 1b trial and plans to expand globally, including China in 2023. Despite a net loss of $10.5 million in Q3 2022, Eledon maintains adequate financial resources with $65.9 million in cash, enough to sustain operations into 2024.

Eledon Pharmaceuticals (NASDAQ: ELDN) will release its third-quarter financial results for the period ended September 30, 2022, on November 14, 2022, after market close. A conference call and webcast to discuss these results will take place at 4:30 PM ET on the same day. Eledon focuses on developing treatments targeting the CD40L pathway, with its lead candidate being tegoprubart, intended for organ transplant recipients, autoimmune disease patients, and those with ALS. The event will be archived on the company's website for one year.

Eledon Pharmaceuticals (NASDAQ: ELDN) announces its participation in two significant medical conferences this November. At the American Society of Nephrology's Kidney Week 2022 (November 3-6 in Orlando, FL), Eledon will present two posters focusing on the safety and efficacy of tegoprubart in treating IgA nephropathy and its potential for ALS. Additionally, a poster on tegoprubart's safety profile in ALS will be showcased at the Northeast Amyotrophic Lateral Sclerosis Consortium (NEALS) conference (November 1-3 in Clearwater Beach, FL). Eledon specializes in treatments for autoimmune diseases and organ transplant needs.

Eledon Pharmaceuticals, Inc. (NASDAQ: ELDN) announced participation in two upcoming conferences. On October 6, Steven Perrin, Ph.D., will engage in a panel discussion on ALS treatment at the Cantor Neurology & Psychiatry Conference. On October 7, Jeff Bornstein, M.D., will present on the safety and efficacy of tegoprubart for ALS patients at the ALS One 5th Annual ALS Research Symposium. Both presentations are exclusive to registered attendees. Eledon focuses on developing therapies targeting the CD40L pathway for organ transplant, autoimmune diseases, and ALS.

Eledon Pharmaceuticals (NASDAQ: ELDN) announced that CEO David-Alexandre C. Gros will participate in a fireside chat at the Ladenburg Thalmann Healthcare Conference on September 29, 2022, at 2:00 p.m. ET in New York City. Interested parties can register for the webcast here. A replay will be available afterward on the company’s website.

Eledon specializes in developing treatments targeting the CD40 Ligand pathway for transplant patients and those with autoimmune diseases.

Eledon Pharmaceuticals has announced FDA clearance of its IND application for tegoprubart, aimed at treating IgA Nephropathy (IgAN). The Phase 2a clinical trial, now active in 10 countries including the U.S., will evaluate safety and efficacy in patients with severe proteinuria. The study's primary endpoint focuses on changes in urine protein levels after 24 weeks. Currently, IgAN affects around 150,000 Americans, underscoring the urgency for effective treatments amid limitations of standard therapies.

Eledon Pharmaceuticals, listed on NASDAQ as ELDN, announced its participation in two investor conferences. The first event is a fireside chat at the Gilmartin Group Emerging Growth Company Showcase on August 31, 2022, at 2:00 p.m. ET. The second event is a presentation at the H.C. Wainwright 24th Annual Global Investment Conference, available on-demand from September 12, 2022, at 7:00 a.m. ET. Webcast replays will be accessible on the company's website. Eledon focuses on developing treatments targeting the CD40 Ligand pathway, with its lead candidate being tegoprubart.

Eledon Pharmaceuticals (NASDAQ: ELDN) received FDA clearance for a Phase 2 trial of tegoprubart, aimed at preventing organ rejection in kidney transplant patients. The company has initiated a Phase 1b trial with the first patient dosed in Canada, the UK, and Australia. Positive topline results were reported from a Phase 2a trial of tegoprubart in ALS, showing safety, target engagement, and biomarker response. The drug also received Orphan Drug Designation for pancreatic islet cell transplantation. Eledon plans to provide further data in Q1 2023.

Eledon Pharmaceuticals, Inc. (NASDAQ: ELDN) plans to release its financial results for Q2 2022 on August 11, after market close. Management will host a conference call and webcast at 4:30 pm ET to discuss these results. Eledon specializes in developing treatments for organ transplantation, autoimmune diseases, and neurodegenerative disorders, focusing on its lead compound, tegoprubart. This anti-CD40L antibody targets a key biological pathway, promising significant therapeutic potential.